Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
about
Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assemblySYK is a critical regulator of FLT3 in acute myeloid leukemiaPerturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsDownstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsMidostaurin: an emerging treatment for acute myeloid leukemia patientsMolecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyThe Novel PKCθ from Benchtop to ClinicAn overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentCIViC databaseThe structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteineValidation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.'Acute myeloid leukemia: a comprehensive review and 2016 update'FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesMolecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeuticsSelective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia PatientsDiscovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDFLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemiaFinal report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemiaPhosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) CellsTargeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaPhase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaTreatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.The Biology and Targeting of FLT3 in Pediatric Leukemia.Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach.An integrated approach to uncover drivers of cancer.The Future of Targeting FLT3 Activation in AML.Treatment of FLT3-ITD acute myeloid leukemia.Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicFLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotypePim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplicationFLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.
P2860
Q24297412-B0894581-CF7E-4C59-B3BB-175CE1FDD7E9Q24337247-7941C9C6-E209-4DA8-8A75-6F04D19C87ECQ24339394-F0322D9B-6027-417D-BA16-BA938026A9EAQ24617091-F51DAD06-AE52-4F72-858F-005388619939Q26749271-B46C8911-ADDD-4D78-B8DB-0D7A2A1E204EQ26749870-A90B9745-A355-4D46-9BCD-6B781F644C76Q27024068-C36E9C03-1244-48C6-9D60-609DFA3F726CQ27027207-53A22D5F-717D-430F-89F9-2B5E1CBA7F32Q27612411-F05ADE83-E94A-4984-9656-595579280383Q27700733-09487CB7-837C-4E60-B52C-8C1B5261360BQ27851767-E6E5DCC7-476F-47B7-9D0A-E7F2D0FA8436Q27852623-73CD67DB-0E71-403F-83B7-7059856A0A7EQ28072539-0BFDE40F-3F35-4428-A6E0-4AAC87A9990DQ28289859-7119DED1-4904-4CF4-8D82-F0190B1E9ED5Q28394310-2BE48AEE-9E68-43FF-BA16-D9D7320565CCQ28544659-5F9479BB-6CEA-44D3-89D1-C182DB46FD7FQ33442949-0868A68D-47B8-4D31-84B2-4BB1CA6996C1Q33555287-BFEA61F6-56E8-4FCF-8A43-01B16D11AA48Q33749036-5A5079BB-C21C-4280-B37D-6A1AC4DB352BQ33767026-835563D4-EA64-48DD-B5FC-D52693EC4B0CQ33798909-C1A3F679-1A75-4B63-A65E-8B853525283FQ33856839-DFE3132F-46A8-41E3-B872-9F2076CF702FQ33880828-E6D05CCC-50BA-4B30-8A8B-31F987493EF5Q33882022-3BDCB11E-DC91-4F35-87FA-699F0A239007Q33903030-59291D5C-70F9-49FA-B69B-01B3F4B892DEQ33943277-2695B613-FC3A-4DB7-AC9F-D153020AF93EQ33986236-68179872-55D9-43BF-9A32-D152A224DB13Q34004131-E287F1E4-AF0F-4533-800B-83CFBA0E3488Q34011740-251C41B7-69D9-4752-90A2-A5A443A69541Q34229555-DD5CE837-8A81-42C2-81E3-E616456601D5Q34423170-253B46DF-F8EC-4207-B88D-F271506F7339Q34453995-758A9AC5-ADE2-45CD-A6B0-162A56359788Q34555386-6FB8B74C-7122-498D-AA6C-847AA2B2C415Q34636735-FD57695A-BB23-44E6-90A2-03CB7BFE62D6Q34640779-03C2721A-CAC0-431A-9E7F-C1BBAD05A38EQ34647741-8C6AD988-A1AD-4A9F-9F9E-A038BB4D2A48Q34817365-2ECE4901-8829-4E31-A8A0-1BB39EE392B5Q34890418-5156298E-AE70-4BF2-AF52-01EFC39CC630Q34990221-5C94B898-BFCC-4888-A58E-4D5F8948DD7EQ34993145-BC212157-587B-42DD-854F-D66AE8258A83
P2860
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase IIB trial of oral Midost ...... her wild-type or mutated FLT3.
@ast
Phase IIB trial of oral Midost ...... her wild-type or mutated FLT3.
@en
Phase IIB trial of oral Midost ...... her wild-type or mutated FLT3.
@nl
type
label
Phase IIB trial of oral Midost ...... her wild-type or mutated FLT3.
@ast
Phase IIB trial of oral Midost ...... her wild-type or mutated FLT3.
@en
Phase IIB trial of oral Midost ...... her wild-type or mutated FLT3.
@nl
altLabel
Phase IIB Trial of Oral Midost ...... ther Wild-Type or Mutated FLT3
@en
prefLabel
Phase IIB trial of oral Midost ...... her wild-type or mutated FLT3.
@ast
Phase IIB trial of oral Midost ...... her wild-type or mutated FLT3.
@en
Phase IIB trial of oral Midost ...... her wild-type or mutated FLT3.
@nl
P2093
P2860
P3181
P356
P1476
Phase IIB trial of oral Midost ...... her wild-type or mutated FLT3.
@en
P2093
Alice Huntsman-Labed
Carlo Lanza
Catherine Dutreix
D Gary Gilliland
Daniel J Deangelo
Edward Fox
Elihu Estey
Eric J Feldman
Francis J Giles
Gary J Schiller
P2860
P304
P3181
P356
10.1200/JCO.2010.28.9678
P407
P577
2010-10-01T00:00:00Z